Skip to main content

Genome Therapeutics, AstraZeneca Anti-Ulcer R&D Work Moves Forward

NEW YORK, March 20-Genome Therapeutics said today that it had chosen a compound series to optimize as part of its anti-ulcer research and development partnership with AstraZeneca.


The companies chose the compounds through genomic screening combined with biochemical and microbiological analysis.


Genome Therapeutics has sequenced the genome of Helicobacter pylori, the bacterium associated with peptic ulcers, and has used that knowledge to identify genes and develop assays that will improve research into new anti-ulcer treatments.


In 1995, the company struck a $23 million alliance with AstraZeneca. The two firms have collaborated on projects to determine genetic variability and new potential drug targets in H. pylori.


H. pylori, a common bacterial pathogen that lives in the stomach and gastric tract, has been linked to gastritis, ulcers, and certain forms of stomach cancer.


Genome Therapeutics, based in Waltham, Mass., is publicly owned.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.